1. Home
  2. DMLP vs NNNN Comparison

DMLP vs NNNN Comparison

Compare DMLP & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DMLP

Dorchester Minerals L.P.

HOLD

Current Price

$28.73

Market Cap

1.3B

Sector

Energy

ML Signal

HOLD

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

N/A

Current Price

$32.00

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DMLP
NNNN
Founded
2003
2021
Country
United States
Germany
Employees
26
27
Industry
Oil & Gas Production
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
DMLP
NNNN
Price
$28.73
$32.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
160.6K
12.1K
Earning Date
05-07-2026
04-07-2026
Dividend Yield
9.98%
N/A
EPS Growth
N/A
N/A
EPS
0.59
N/A
Revenue
$152,832,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$47.73
$446.57
Revenue Growth
N/A
N/A
52 Week Low
$20.85
$7.23
52 Week High
$28.95
$55.65

Technical Indicators

Market Signals
Indicator
DMLP
NNNN
Relative Strength Index (RSI) 63.97 67.19
Support Level $23.97 $26.31
Resistance Level $28.77 $32.94
Average True Range (ATR) 0.67 2.38
MACD 0.15 0.23
Stochastic Oscillator 95.82 90.66

Price Performance

Historical Comparison
DMLP
NNNN

About DMLP Dorchester Minerals L.P.

Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits, and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonuses, and others.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

Share on Social Networks: